You are here: Industry Insights > BioLineRx

News List

BioLineRx Announces Initiation of Triple Combination Arm of Pancreatic Cancer Study americanpharmaceuticalreview
December 12, 2018
BioLineRx announced the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in patients with metastatic pancreatic cancer (PDAC) under its immuno-oncology.....
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy americanpharmaceuticalreview
May 18, 2018
Mobilization of hematopoietic stem and progenitor cells (HSPCs) for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5 day treatment cycle with G-CSF and a 1-2 day apheresis procedure.
BioLineRx Announces Partial Monotherapy Results From Phase IIa COMBAT Study in Pancreatic Cancer biospace
January 18, 2018
Partial results of the monotherapy portion of Phase 2a COMBAT study of BL-8040 showed that BL-8040 increased the tumor invasion of tumor and immune infiltrating T cells into patients with metastatic pancreatic cancer.
BioLineRx Announces Initiation Stem-Cell Mobilization for Autologous Transplantation Trial americanpharmaceuticalreview
December 26, 2017
BioLineRx Announces Launch of Phase III GENESIS Clinical Trial，，，
BioLineRx Announces Submission of Phase 3 Registrational Study for BL-8040 pharmaceutical-technology
August 23, 2017
BioLineRx announced the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myelom

Previous page 1 2 Next page